|
Affiliation |
Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Pediatrics |
|
Title |
Professor |
|
External Link |
|
|
Related SDGs |
|
MORITAKE Hiroshi
|
|
|
Research Areas 【 display / non-display 】
-
Life Science / Embryonic medicine and pediatrics
-
Life Science / Hematology and medical oncology
Papers 【 display / non-display 】
-
Aoki Y., Nakai M., Sawada H., Moritake H.
European Journal of Pediatrics 185 ( 11 ) 2026.10
Language：English Publishing type：Research paper (scientific journal) Publisher：European Journal of Pediatrics
This study aimed to examine whether preterm birth is associated with thinness and differences in body mass index (BMI) trajectories at ages 3-6 years. This cohort study used data from the Japan Environment and Children's Study, a nationwide birth cohort. Among 100,121 live births, 93,406 children were included. Preterm birth was defined as < 37 weeks' gestation. Thinness was defined as BMI-for-age < - 2 standard deviations according to World Health Organization criteria. Multivariable logistic regression was used to examine associations between preterm birth and thinness at each age. Longitudinal changes in BMI were analysed using linear mixed-effects models. Preterm birth was associated with higher odds of thinness at most ages: adjusted odds ratios were 1.35 (95% confidence interval [CI], 0.94-1.93) at age 3 years, 1.43 (95% CI, 1.02-1.99) at 4 years, 1.70 (95% CI, 1.29-2.25) at 5 years, and 1.52 (95% CI, 1.20-1.92) at 6 years. Findings were consistent with sensitivity analyses using an alternative definition of thinness. In the longitudinal analysis, mean BMI was consistently lower among preterm-born children, with mean BMI differences of 0.11-0.19 kg/m2 across ages 3-6 years, and no evidence of convergence over time. CONCLUSION: Preterm birth was associated with lower BMI trajectories and higher odds of thinness during early childhood. These findings suggest that incorporating gestational age into growth assessment and monitoring body mass, in addition to linear growth, may help identify children with lower BMI trajectories. WHAT IS KNOWN: • Children born preterm have heterogeneous postnatal growth trajectories, with previous studies reporting both increased risk of obesity and lower body mass during childhood. • Large-scale longitudinal evidence on BMI and thinness during early childhood among children born preterm remains limited. WHAT IS NEW: • In this nationwide birth cohort, preterm birth was associated with higher odds of thinness at ages 4-6 years. • Children born preterm also had consistently lower BMI at ages 3-6 years, with no evidence of convergence with term-born children.
-
Fagniez I, Tsumura M, Guérin A, Abolhassani H, Sharafian S, Mesdaghi M, Nishimura T, Lashkari HP, Rao S, Richards S, Han JE, Delmonte OM, Kergaravat C, Markle JG, Ogishi M, Han J, Peel J, Vellutini J, Feng Y, Soudée C, Migaud M, Palterer B, Jackson KJL, Nishimura S, Sakata S, Kinoshita K, Yamamoto A, Moritake H, Alzahrani M, Vallejos F, Cole T, Smart JM, Choo S, Chavoshzadeh Z, Armin S, Toubert A, Zhang P, Rosain J, Notarangelo LD, Pan-Hammarström Q, Tangye SG, Casanova JL, Ma CS, Puel A, Bustamante J, Okada S, Boisson-Dupuis S, Yang R
The Journal of experimental medicine 223 ( 10 ) e20252038 2026.10
Language：English Publishing type：Research paper (scientific journal) Publisher：Rockefeller University Press
We previously reported inherited RORγT deficiency in seven patients from three ancestries (Chilean, Palestinian, Saudi Arabian) with mycobacterial disease and chronic mucocutaneous candidiasis (CMC). We report here five additional patients from different ancestries (Afghan, Indian, Iranian, Japanese, Sri Lankan), each homozygous for a new loss-of-function RORC variant. All but one patient — the exception receiving early prophylaxis — developed mycobacterial disease due to a near-complete depletion of innate-like adaptive T cells, including MAIT and iNKT cells, low counts of adaptive TH1* and CD8+ T cells, and impaired Mycobacterium-induced IFN-γ production by the remaining cells of these subsets, NK cells, conventional CD4+ T, Vδ1, and Vδ2 γδT cells. Most patients also displayed CMC due to their low counts of TH17 and TH1* cells. One patient died from disseminated Bacille Calmette-Guérin (BCG) vaccine infection, but, unexpectedly, all the other patients are still alive and clinically stable at ages of two to 20 years. RORγT is essential for protective immunity against mycobacteria and Candida in humans.
DOI： 10.1084/jem.20252038
-
兒玉 祥彦, 河野 朋宏, 沖田 典子, 渡邉 望, 盛武 浩
Vascular medicine 1358863X261476682 2026.10
Language：English Publishing type：Research paper (scientific journal) Publisher：SAGE Publications
Background:
Osteogenesis imperfecta (OI) is a congenital bone fragility disorder, in which 90% of patients have abnormalities in type 1 collagen. Cardiovascular complications, including valvular heart disease and vascular aneurysms, are reportedly comorbid with this disease.
Methods:
Forty-three adult Japanese patients clinically diagnosed with OI were recruited. Participants underwent echocardiography, brain magnetic resonance imaging (MRI), and magnetic resonance angiography. We compared the prevalence of cardiovascular comorbidities with that of a healthy Japanese population using direct age-standardization and a one-sample binomial test.
Results:
The median age was 42.5 (IQR 37.4–53.5) years. OI severity was mild in 11, moderate in 11, and severe in 21 patients. Two patients had ⩾ moderate aortic regurgitation (moderate OI: 1; severe OI: 1), one patient had severe mitral regurgitation (moderate OI: 1), and another had previously received valvuloplasty for mitral regurgitation (mild OI: 1). The prevalence of valvular heart disease (9.3%) was significantly higher than that of the healthy Japanese population (0.8%) (p < 0.001). Five patients (11.6%) had unruptured intracranial aneurysms (UIAs) (mild OI: 2; severe OI: 3), and the prevalence was significantly higher than that of the healthy Japanese population (2.5%) (p < 0.005). Notably, two patients presented with both valvular heart disease and a UIA. Additionally, 27 patients (62.8%) had tortuosity in the intracranial arteries, and seven patients (16.3%) had significant cortical atrophy.
Conclusion:
This study revealed an increased prevalence of valvular heart disease, UIAs, and possibly intracranial arterial tortuosity and cortical atrophy among adults with clinically diagnosed OI. Routine echocardiography, and brain MRI and MRA are recommended regardless of disease severity. -
Nakashima K., Hasegawa D., Matsubayashi J., Tanaka S., Hama A., Yamato G., Kato S., Honda M., Nagai K., Goto H., Tsujimoto S.I., Deguchi T., Niwa K., Hiramatsu H., Terui K., Toki T., Yoshida K., Kawai T., Saito A.M., Moritake H., Taga T., Okamoto Y., Koh K., Tomizawa D.
BMJ Open 16 ( 9 ) e115972 2026.9
Language：English Publishing type：Research paper (scientific journal) Publisher：BMJ Open
INTRODUCTION: The prognosis of myeloid leukaemia associated with Down syndrome (ML-DS) is excellent with reduced-intensity chemotherapy; however, that of refractory or relapsed ML-DS remains dismal. These contrasting outcomes highlight the importance of risk-stratified therapy, based on reliable prognostic factors, to prevent treatment-related mortality and relapse. In addition, novel therapeutic strategies capable of overcoming the poor prognosis of high-risk patients are eagerly anticipated. Based on the results of molecular analyses, in vitro functional assays and anecdotal case reports, azacitidine (AZA), a hypomethylating agent, is a promising candidate for novel therapeutic strategies for high-risk ML-DS. METHODS AND ANALYSIS: In this multicentre, single-arm phase II clinical trial, the Japan Children's Cancer Group AML-D24, we will stratify patients with newly diagnosed ML-DS according to age at diagnosis, GATA1 mutation status and treatment response. Patients <24 months of age at the diagnosis with a GATA1 mutation who achieve morphological complete remission and are negative for flow cytometric measurable residual disease at the end of induction will be classified as the low-risk (LR) group and receive less intensive chemotherapy. The other participants, stratified into the non-LR group, will be treated with AZA-combined chemotherapy. The objective of this trial is to evaluate the efficacy and safety of AZA-combined chemotherapy in children with non-LR ML-DS. The primary endpoint is the 3-year event-free survival in the non-LR group. The planned enrolment is 145 patients, including 47 non-LR patients. The study period consists of a 7-year accrual period (including an enrolment suspension period for interim analysis) followed by a 3-year follow-up period for a total duration of 10 years. ETHICS AND DISSEMINATION: This study was approved by the National Hospital Organization Review Board for Clinical Trials (Nagoya, Japan) on 12 May 2025 and was registered in the Japan Registry of Clinical Trials (https://jrct.mhlw.go.jp/latest-detail/jRCTs041250031). Written informed consent will be obtained from all patients and/or their guardians. The results of this study will be disseminated through publication in peer-reviewed journals and presentation at national and international scientific conferences. TRIAL REGISTRATION NUMBER: jRCTs041250031.
-
Outdoor play and catch-up growth in small-for-gestational-age children: a nationwide prospective birth cohort study from the Japan environment and children's study. Reviewed
Aoki Y, Nakai M, Sawada H, Moritake H, Japan Environment and Children’s Study Group
BMC public health 26 ( 1 ) 2026.8
Language：English Publishing type：Research paper (scientific journal)
Books 【 display / non-display 】
-
今日の治療指針
盛武 浩（ Role： Joint author , 小児の白血病）
医学書院 2021 （ ISBN:978-4-260-04283-3 ）
Responsible for pages：1494-1495 Language：Japanese Book type：Textbook, survey, introduction
-
血液専門医テキスト 改訂第3版
盛武 浩（ Role： Joint author , 小児の急性骨髄性白血病）
南江堂 2019
Responsible for pages：456-460 Language：Japanese Book type：Textbook, survey, introduction
-
鉄欠乏性貧血. 小児疾患診療のための病態生理3 改訂第5版.
盛武 浩（ Role： Sole author）
東京医学社 2016
Language：Japanese Book type：Textbook, survey, introduction
-
白血球と分画
盛武 浩（ Role： Sole author）
今日の小児診断指針 2004.7
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
Successful Treatment of Mediastinal Anthracycline Extravasation by Administration of Dexrazoxane Reviewed
Kuroki Y., Nagasawa S., Yamada A., Moritake H.
Pediatric Blood and Cancer 73 ( 2 ) e70026 2026.2
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Pediatric Blood and Cancer
-
T1 mapping on cardiac magnetic resonance of myocardial calcification after septic shock Reviewed
Takahashi M., Kodama Y., Takamura K., Enzaki M., Nagasawa S., Yamada A., Moritake H.
Pediatrics International 68 ( 1 ) e70337 2026.1
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Pediatrics International
DOI： 10.1111/ped.70337
-
Nagasawa S., Yamada A., Nakamura E., Oba U., Moritake H.
Pediatrics International 68 ( 1 ) e70399 2026.1
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Pediatrics International
DOI： 10.1111/ped.70399
-
Tomizawa D., Matsubayashi J., Iwamoto S., Hiramatsu H., Hasegawa D., Moritake H., Hasegawa D., Terui K., Hama A., Tsujimoto S.I., Kiyokawa N., Miyachi H., Deguchi T., Hashii Y., Iijima-Yamashita Y., Taki T., Noguchi Y., Koike K., Koh K., Yuza Y., Saito A.M., Horibe K., Taga T., Tanaka S., Adachi S.
Leukemia 38 ( 1 ) 202 - 206 2024
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Leukemia
-
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia Reviewed
Iyoda S., Yoshida K., Shoji K., Ito N., Tanaka M., Nannya Y., Yamato G., Tsujimoto S., Shiba N., Hayashi Y., Shiozawa Y., Shiraishi Y., Chiba K., Okada A., Tanaka H., Miyano S., Koga Y., Goto H., Moritake H., Terui K., Ito E., Kiyokawa N., Tomizawa D., Taga T., Tawa A., Takita J., Nishikori M., Adachi S., Ogawa S., Matsuo H.
Leukemia 38 ( 7 ) 1609 - 1612 2024
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Leukemia
Presentations 【 display / non-display 】
-
COVID-19 ワクチン接種後に発症した心膜心筋炎
二見 加菜、髙村 一成、山下 尚人、原田 雅子、澤 大介、盛武 浩
第91回日本小児科学会宮崎地方会, 宮崎
Event date： 2022.3.20
Presentation type：Oral presentation (general)
-
発症早期に免疫修飾治療を開始したラスムッセン脳炎
山本 夏穂、 下田 貴史、 森 こずえ、 前田 謙一、 木許 恭宏、 池田 俊郎、 盛武 浩
第91回日本小児科学会宮崎地方会, 宮崎
Event date： 2022.3.20
Presentation type：Oral presentation (general)
-
集団健診を契機に診断された頻拍誘発性心筋症２例
興梠 智子、髙村 一成、山下 尚人、原田 雅子、盛武 浩
第91回日本小児科学会宮崎地方会, 宮崎
Event date： 2022.3.20
Presentation type：Oral presentation (general)
-
Clonal architecture and its prognostic significance in KMT2A-rearranged acute myeloid leukemia
Matsuo H, Yoshida K, Nannya Y, Kamikubo Y, Saito S, Koga Y, Moritake H, Terui K, Kawaguchi K, Okamoto Y,Nakayama H, Kanno M, Hino M, Akane Y, Inoue A, Shimada A, Goto H, Ueno H, Takita J, Yamato G, Shiba N, Hayashi Y, Shiraishi Y, Miyano S, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Ogawa S, Adachi S
Event date： 2021.9.23 - 2021.9.25
Presentation type：Oral presentation (general)
-
不明熱を呈し, リンパ節生検により診断に至ったTAFRO症候群の１例
小川 智香, 山元 綾子, 西村 豊樹, 盛武 浩
第90回日本小児科学会宮崎地方会, 宮崎
Event date： 2021.9.12
Presentation type：Oral presentation (general)
Awards 【 display / non-display 】
-
日本白血病研究基金 一般研究賞（クレディセゾン賞）
2014.11 公益信託 日本白血病研究基金助成事業
盛武 浩
Award type：Award from publisher, newspaper, foundation, etc. Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
PDXマウスモデルを用いた再発難治小児急性骨髄性白血病の病態解明と新規治療法開発
Grant number：23K07337 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究(C)
Authorship：Principal investigator
-
Mfsd2遺伝子KOマウスを用いた、脳内ＤＨＡによるエネルギー代謝調節機構の解明
Grant number：16K09971 2018.04
科学研究費補助金 基盤研究(C)
KOマウスの脳の組織学的評価と、摂食行動およびエネルギー代謝特性、代謝関連遺伝子発現を評価する。
-
網羅的遺伝子解析をとおして同定した家族性白血病原因遺伝子の機能解析
Grant number：16K10032 2016.04 - 2019.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
網羅的遺伝子解析をとおして同定した家族性白血病原因遺伝子と想定される2つの遺伝子変異の機能解析を行う
-
家族性急性リンパ性白血病の原因遺伝子の探索
Grant number：25461600 2013.04 - 2016.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
家族性急性リンパ性白血病の原因遺伝子の探索
-
Mfsd2遺伝子ノックアウトマウスにおけるエネルギー代謝特性の解明
Grant number：25461556 2013.04 - 2015.03
科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)
我々が作成したMfsd2遺伝子ノックアウトマウスにおけるエネルギー代謝特性を解析する